ARTICOLI ORIGINALI   

Minerva Endocrinologica 2014 September;39(3):209-14

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

Serum nesfatin-1 levels in overt and subclinical hyperthyroidism

Gungunes A. ¹, Ozbek M. ¹, Ginis Z. ², Sahin M. ³, Demirci T. ¹, Cakir Ozkaya E. ¹, Karbek B. ¹, Sayki Arslan M. ¹, Ozturk Unsal I. ¹, Tutal Akkaya E. ¹, Ucan B. ¹, Gultuna Ozguclu S. ⁴, Cakal E. ¹, Topaloglu O. ¹, Delibasi T. ¹ ✉

¹ Department of Endocrinology and Metabolic Diseases, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; ² Department of Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; ³ Department of Endocrinology and Metabolic Diseases, School of Medicine, Ankara University, Ankara, Turkey; ⁴ Department of Immunology, School of Medicine, Ankara University, Ankara, Turkey

AIM: Nesfatin-1 was recently discovered anorexigenic peptide in the brain which is derived from nucleobindin-2. Central and peripheral administration of nesfatin-1, inhibits food intake, dose-dependently. Hyperthyroid patients have increased appetite and food intake with a craving for carbohydrate-rich food, at the beginning of disease, but the physiological mechanisms underlying this behavior is not known exactly. In this study, we investigated whether nesfatin-1 is involved in the regulation of appetite and body weight in hyperthyroidism, or not.
METHODS: A total of 70 patients with subclinical (35) and overt hyperthyroidism (35) compared with 35 control patients. Serum nesfatin-1 level was measured from all samples by commercial ELISA kit.
RESULTS: Serum nesfatin-1 levels were similar between three groups (P=0.293). After adjusting for age and body mass index, nesfatin-1 levels in control group was not different from subclinical and overt hyperthyroid group, respectively (P=0.567 and P=0.519).
CONCLUSION: These data showed that serum nesfatin-1 levels do not significant change in overt and subclinical hyperthyroidism.